[vc_row][vc_column][vc_column_text]
Dr José F. Alfonso Sánchez, head of the Unit of Anterior Segment and Ocular Surface at Instituto Oftalmológico Fernández-Vega, will head the Alcon Chair of innovation in surgery for emmetropia that arises with the aim of increasing the activity that has been taking on sporadically the holder of the position and to provide it with a stable framework. This way, far-reaching projects will be developed in the area of ophthalmology, with a special focus on this kind of eye surgery. This physician from the Institute is, at the same time, professor in the area of ophthalmic knowledge at Universidad de Oviedo.
The vice-chancellor of Universidad de Oviedo, Mr Vicente Gotor, and the Director General at Alcon Cusi, Mr Enrique Chico Picaza, have entered into the agreement from which this chair arose.
Three representatives of each institution will form the management committee of the chair. On behalf of ALCON CUSI SA, Mr Enrique Chico Picaza, Mr Antonil Maneu Marcos and Mr Pedro Coloma Romero; and on behalf of Universidad de Oviedo, Dr José F. Alfonso Sánchez – as Director of the chair – Prof Luis Fernández-Vega Sanz – head of Ophthalmology at the Asturian teaching institution – and Dr Jesús Merayo Lloves – professor of ophthalmology at the same university and coordinator of research and teaching at the Institute and its Foundation – Fundación de Investigación Oftalmológica.
During the agreement signing ceremony, the vice-chancellor expressed his appreciation towards this kind of initiatives and said that it “is a pleasure for the University that companies invest in research. One of my battlefields is that without research we wont emerge from the crisis”.
For his part, Prof Luis Fernández-Vega highlighted that this kind of agreements boost the relationship of the industry with the University and “opens a path to hire researchers, without cost for the academic institution”
Finally, the director general at Alcon was very keen about the project and said that his company has “always turned to innovation and research, to which we allocate over 13% of our general budget”.
[/vc_column_text][/vc_column][/vc_row]
